Skip to main content
SpringerLink
Log in

Advances in the Diagnosis and Treatment of Premenstrual Dysphoria

  • Review Article
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

The recent inclusion of research diagnostic criteria for premenstrual dysphoric disorder (PMDD) in the DSM-IV recognises the fact that some women in their reproductive years have extremely distressing emotional and behavioural symptoms premenstrually. Through the use of these criteria, PMDD can be differentiated from premenstrual syndrome (PMS) which has milder physical symptoms, i.e. breast tenderness, bloating, headache and minor mood changes. PMDD can also be differentiated from premenstrual exacerbation of a current psychiatric disorder or medical condition, although some women may meet criteria for a dual diagnosis.

Epidemiological surveys have estimated that as many as 75% of women with regular menstrual cycles experience some symptoms of PMS. PMDD, on the other hand, is much less common. It affects only 3 to 8% of women in this group, but it is more severe and exerts a much greater psychological toll. These women report premenstrual symptoms that seriously interfere with their lifestyle and relationships. The aetiology of PMDD is largely unknown but the current consensus seems to be that normal ovarian function (rather than hormone imbalance) is the cyclical trigger for PMDD-related biochemical events within the CNS and other target organs.

The serotonergic system is in close reciprocal relationship with the gonadal hormones and has been identified as the most plausible target for interventions. Thus, beyond the conservative treatment options such as lifestyle and stress management, and the more extreme interventions that eliminate ovulation altogether, the selective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors (SSRIs) are emerging as the most effective treatment options for this population.

Results from several randomised placebo-controlled trials in women with PMDD, with predominantly psychological symptoms of irritability, tension, dysphoria and lability of mood, have clearly demonstrated that the SSRIs have excellent efficacy and minimal adverse effects. More recently, several preliminary studies indicate that intermittent (premenstrually only) treatment with SSRIs is equally effective in these women and, thus, may offer an attractive treatment option for a disorder that is itself intermittent.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

Similar content being viewed by others

References

  1. Endicott J, Amsterdam, J, Eriksson E, et al. Is premenstrual dysphoric disorder a distinct clinical entity? J Women’s Health Gender-Based Med 1999; 8: 663–79

    Article  CAS  Google Scholar 

  2. World Health Organization. Tenth revision of the International Classification of Diseases (ICD-10). Geneva: World Health Organization Publishers, 1996: 717

    Google Scholar 

  3. Budeiri DJ, Li Wan Po A, Dornan JC. Clinical trials of treatments of premenstrual syndrome: entry criteria and scales for measuring treatment outcomes. Br J Obstet Gynaecol 1994; 101:689–95

    Article  PubMed  CAS  Google Scholar 

  4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd rev. ed. Washington, DC: American Psychiatric Association, 1987: 367–9

    Google Scholar 

  5. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994: 717–8

    Google Scholar 

  6. Steiner M, Wilkins A, Diagnosis and assessment of premenstrual dysphoria. Psychiatr Ann 1996; 26: 571–5

    Google Scholar 

  7. Johnson SR. The epidemiology and social impact of premenstrual symptoms. Clin Obstet Gynecol 1987; 30: 367–76

    Article  PubMed  CAS  Google Scholar 

  8. Greene R, Dalton K. The premenstrual syndrome. BMJ 1953; 1: 1007–14

    Article  PubMed  CAS  Google Scholar 

  9. Haskett RF, DeLongis A, Kessler RC. Premenstrual dysphoria: a community survey. Presented at Annual American Psychiatric Association Meeting: 1987 May; Chicago

  10. Johnson SR, McChesney C, Bean JA. Epidemiology of premenstrual symptoms in a nonclinical sample. I. Prevalence, natural history and help-seeking behaviour. J Reprod Med 1988; 33: 340–6

    PubMed  CAS  Google Scholar 

  11. Rivera-Tovar AD, Frank E. Late luteal phase dysphoric disorder in young women. Am J Psychiatry 1990; 147: 1634–6

    PubMed  CAS  Google Scholar 

  12. Andersch B, Wendestam C, Hahn L, et al. Premenstrual complaints. I. Prevalence of premenstrual symptoms in a Swedish urban population. J Psychosom Obstet Gynaecol 1986; 5: 39–49

    Article  Google Scholar 

  13. Merikangas KR, Foeldenyi M, Angst J. The Zurich Study. XIX. Patterns of menstrual disturbances in the community: results of the Zurich Cohort Study. Eur Arch Psychiatry Clin Neurosci 1993; 243: 23–32

    Article  PubMed  CAS  Google Scholar 

  14. Ramcharan S, Love EJ, Fick GH, et al. The epidemiology of premenstrual symptoms in a population based sample of 2650 urban women. J Clin Epidemiol 1992; 45: 377–81

    Article  PubMed  CAS  Google Scholar 

  15. Freeman EW, Sondheimer K, Weinbaum PH, et al. Evaluating premenstrual symptoms in medical practice. Obstet Gynecol 1985; 65: 500–5

    PubMed  CAS  Google Scholar 

  16. O’Brien PMS, Abukhalil IEH, Henshaw C. Premenstrual syndrome. Curr Obstet Gynecol 1995; 5: 30–7

    Article  Google Scholar 

  17. Hendrick V, Altshuler LL, Burt VK. Course of psychiatric disorders across the menstrual cycle. Harv Rev Psychiatry 1996; 4: 200–7

    Article  PubMed  CAS  Google Scholar 

  18. Bailey JW, Cohen LS. Prevalence of mood and anxiety disorders in women who seek treatment for premenstrual syndrome. J Womens Health Gend Based Med 1999; 8:1181–4

    Article  PubMed  CAS  Google Scholar 

  19. Blehar MC, DePauloJr JR, Gershon ES, et al. Women with bipolar disorder: findings from the NIMH Genetics Initiative sample. Psychopharmacol Bull 1998; 34: 239–43

    PubMed  CAS  Google Scholar 

  20. Yonkers KA. The association between premenstrual dysphoric disorder and other mood disorders. J Clin Psychiatry 1997; 58 Suppl. 15: 19–25

    PubMed  Google Scholar 

  21. Yonkers KA. Anxiety symptoms and anxiety disorders: how are they related to premenstrual disorders. J Clin Psychiatry 1997; 58 Suppl. 3: 62–7

    PubMed  Google Scholar 

  22. Freeman EW, Rickels K, Schweizer E, et al. Relationships between age and symptom severity among women seeking medical treatment for premenstrual symptoms. Psychol Med 1995; 25: 309–15

    Article  PubMed  CAS  Google Scholar 

  23. Deuster PA, Adera T, South-Paul J. Biological, social, and behavioral factors associated with premenstrual syndrome. Arch Fam Med 1999; 8: 122–8

    Article  PubMed  CAS  Google Scholar 

  24. Woods NF, Most A, Dery GK. Prevalence of perimenstrual symptoms. Am J Public Health 1982; 72: 1257–64

    Article  PubMed  CAS  Google Scholar 

  25. Hargrove JT, Abraham GE. The incidence of premenstrual tension in a gynecologic clinic. J Reprod Med 1982; 27: 721–4

    PubMed  CAS  Google Scholar 

  26. Pearlstein TB, Frank E, Rivera-Tovar A, et al. Prevalence of axis I and axis II disorders in women with late luteal phase dysphoric disorder. J Affect Disord 1990; 20: 129–34

    Article  PubMed  CAS  Google Scholar 

  27. Parry BL. Mood disorders linked to reproductive cycle in women. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York (NY): Raven Press, 1995: 1029–42

    Google Scholar 

  28. Harrison WM, Endicott J, Nee J, et al. Characteristics of women seeking treatment for premenstrual syndrome. Psychosomatics 1989; 30: 405–11

    Article  PubMed  CAS  Google Scholar 

  29. Fava M, Pedrazzi F, Guaraldi GP, et al. Comorbid anxiety and depression among patients with late luteal phase dysphoric disorder. J Anxiety Disord 1992; 6: 325–35

    Article  Google Scholar 

  30. McLeod DR, Hoehn-Saric R, Foster GV, et al. The influence of premenstrual syndrome on ratings of anxiety in women with generalized anxiety disorder. Acta Psychiatr Scand 1993; 88: 248–51

    Article  PubMed  CAS  Google Scholar 

  31. Endicott J. The menstrual cycle and mood disorders. J Affect Disord 1993; 29: 193–200

    Article  PubMed  CAS  Google Scholar 

  32. Bancroft J, Rennie D, Warner P. Vulnerability to perimenstrual mood change: the relevance of a past history of depressive disorder. Psychosom Med 1994; 56: 225–31

    PubMed  CAS  Google Scholar 

  33. Kaspi SP, Otto MW, Pollack MH, et al. Premenstrual exacerbation of symptoms in women with panic disorder. J Anxiety Disord 1994; 8: 131–8

    Article  Google Scholar 

  34. Graze KK, Nee J, Endicott J. Premenstrual depression predicts future major depressive disorder. Acta Psychiatr Scand 1990; 81:201–5

    Article  PubMed  CAS  Google Scholar 

  35. Condon JT. The premenstrual syndrome: a twin study. Br J Psychiatry 1993; 162:481–6

    Article  PubMed  CAS  Google Scholar 

  36. Kendler KS, Karkowski LM, Corey LA, et al. Longitudinal population-based twin study of retrospectively reported premenstrual symptoms and lifetime major depression. Am J Psychiatry 1998; 155: 1234–40

    PubMed  CAS  Google Scholar 

  37. Severino SK, Moline ML. Premenstrual syndrome: a clinician’s guide. York (NY): The Guilford Press 1989: 132–5

    Google Scholar 

  38. Paddison PL, Gise LH, Lebovits A, et al. Sexual abuse and premenstrual syndrome: comparison between a lower and higher socioeconomic group. Psychosomatics 1990; 31: 265–72

    Article  PubMed  CAS  Google Scholar 

  39. Dan AJ, Monagle L. Sociocultural influences on women’s experiences of perimenstrual symptoms. In: Gold JH, Severino SK, editors. Premenstrual dysphorias: myths and realities. Washington, DC: American Psychiatric Press, Inc., 1994: 201–11

    Google Scholar 

  40. Chandra PS, Chaturvedi SK. Cultural variations in premenstrual experience. Int J Soc Psychiatry 1989; 35(4): 343–9

    Article  PubMed  CAS  Google Scholar 

  41. Chang AM, Holroyd E, Chau JP. Premenstrual syndrome in employed Chinese women in Hong Kong. Health Care Women Int 1995; 16: 551–61

    Article  PubMed  CAS  Google Scholar 

  42. Sveinsdottir H. Prospective assessment of menstrual and premenstrual experiences of Icelandic women. Health Care Women Int 1998; 19: 71–82

    Article  PubMed  CAS  Google Scholar 

  43. Marvan ML, Diaz-Erosa M, Montesinos A. Premenstrual symptoms in Mexican women with different educational levels. J Psychol 1998; 132: 517–26

    Article  PubMed  CAS  Google Scholar 

  44. Schmidt PJ, Nieman LK, Danaceau MA, et al. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med 1998; 338: 209–16

    Article  PubMed  CAS  Google Scholar 

  45. Casson P, Hahn PM, Van Vugt DA, et al. Lasting response to ovariectomy in severe intractable premenstrual syndrome. Am J Obstet Gynecol 1990; 162: 99–105

    PubMed  CAS  Google Scholar 

  46. Casper RF, Hearn MT. The effect of hysterectomy and bilateral oophorectomy in women with severe premenstrual syndrome. Am J Obstet Gynecol 1990; 162: 105–9

    PubMed  CAS  Google Scholar 

  47. Roca CA, Schmidt PJ, Bloch M, et al. Implications of endocrine studies of premenstrual syndrome. Psychiatr Ann 1996; 26: 576–80

    Google Scholar 

  48. Rubinow DR, Schmidt PJ. The treatment of premenstrual syndrome — forward into the past. N Engl J Med 1995; 332: 1574–5

    Article  PubMed  CAS  Google Scholar 

  49. Eriksson E, Sundblad C, Lisjo P, et al. Serum levels of androgens are higher in women with premenstrual irritability and dysphoria than in controls. Psychoneuroendocrinol 1992; 17: 195–204

    Article  CAS  Google Scholar 

  50. Eriksson E, Ailing C, Andersch B, et al. Cerebrospinal fluid levels of monoamine metabolites. Apreliminary study of their relation to menstrual cycle phase, sex steroids, and pituitary hormones in healthy women and in women with premenstrual syndrome. Neuropsychopharmacol 1994; 11: 201–13

    Article  CAS  Google Scholar 

  51. Steiner M, Coote M, Wilkins A, et al. Biological correlates of irritability in women with premenstrual dysphoria [abstract]. Eur Neuropsychopharmacol 1997; 7 Suppl. 2: S172

    Article  Google Scholar 

  52. Eriksson E, Sundblad C, Landén M, et al. Behavioural effects of androgens in women. In: Steiner M, Yonkers K, Eriksson E, editors. Mood disorders in women. London: Martin Dunitz Ltd, 2000

    Google Scholar 

  53. Rowe T, Sasse V. Androgens and premenstrual symptoms — the response to therapy. In: Deneerstein L, Frazer I, editors. Hormones and behaviour. New York (NY): Elsevier Science Publishers, 1986: 160–5

    Google Scholar 

  54. Burnet RB, Radden HS, Easterbrook EG, et al. Premenstrual syndrome and spironolactone. Aust NZ J Obstet Gynaecol 1991; 31: 366–8

    Article  CAS  Google Scholar 

  55. Dougherty DM, Bjork JM, Moeller FG, et al. The influence of menstrual-cycle phase on the relationship between testosterone and aggression. Physiol Behav 1997; 62: 431–5

    Article  PubMed  CAS  Google Scholar 

  56. Bäckström T, Aakvaag A. Plasma prolactin and testosterone during the luteal phase in women with premenstrual tension syndrome. Psychoneuroendocrinol 1981; 6: 245–51

    Article  Google Scholar 

  57. Rubinow DR, Hoban MC, Grover GN, et al. Changes in plasma hormones across the menstrual cycle in patients with menstrually related mood disorder and in control subjects. Am J Obstet Gynecol 1988; 158: 5–11

    PubMed  CAS  Google Scholar 

  58. Bloch M, Schmidt PJ, Su TP, et al. Pituitary-adrenal hormones and testosterone across the menstrual cycle in women with premenstrual syndrome and controls. Biol Psychiatry 1998; 43: 897–903

    Article  PubMed  CAS  Google Scholar 

  59. Hammarback S, Bäckström T, Holst J, et al. Cyclical mood changes as in the premenstrual tension syndrome during sequential estrogen-progestagen postmenopausal replacement therapy. Acta Obstet Gynecol Scand 1985; 64: 393–7

    Article  PubMed  CAS  Google Scholar 

  60. Rapkin AJ, Morgan M, Goldman L, et al. Progesterone metabolite allopregnanolone in women with premenstrual syndrome. Obstet Gynecol 1997; 90: 709–14

    Article  PubMed  CAS  Google Scholar 

  61. Schmidt PJ, Purdy RH, Moore Jr PH, et al. Circulating levels of anxiolytic steroids in the luteal phase in women with premenstrual syndrome and in control subjects. J Clin Endocrinol Metab 1994; 79: 1256–60

    Article  PubMed  CAS  Google Scholar 

  62. Wang M, Seippel L, Purdy RH, et al. Relationship between symptom severity and steroid variation in women with premenstrual syndrome: study on serum pregnenolone, pregnenolone sulfate, 5 α-pregnane-3,20-dione and 3 α-hydroxy-5-alpha-pregnan-20-one. J Clin Endocrinol Metab 1996; 81: 1076–82

    Article  PubMed  CAS  Google Scholar 

  63. Bicikova M, Dibbelt L, Hill M, et al. Allopregnanolone in women with premenstrual syndrome. Horm Metab Res 1998; 30: 227–30

    Article  PubMed  CAS  Google Scholar 

  64. Muneyvirci-Delale O, Nacharaju VL, Altura BM, et al. Sex steroid hormones modulate serum ionized magnesium and calcium levels throughout the menstrual cycle in women. Fertil Steril 1998; 69: 958–62

    Article  PubMed  CAS  Google Scholar 

  65. Thys-Jacobs S, Alvir MJ. Calcium-regulating hormones across the menstrual cycle: evidence of a secondary hyperparathyroidism in women with PMS. J Clin Endocrinol Metab 1995; 80: 2227–32

    Article  PubMed  CAS  Google Scholar 

  66. Korzekwa MI, Lamont JA, Steiner M. Late luteal phase dysphoric disorder and the thyroid axis revisited. J Clin Endocrinol Metab 1996; 81: 2280–4

    Article  PubMed  CAS  Google Scholar 

  67. Nikolai TF, Mulligan GM, Gribble RK, et al. Thyroid function and treatment inn premenstrual syndrome. J Clin Endocrinol Metab 1990; 70: 1108–12

    Article  PubMed  CAS  Google Scholar 

  68. Schmidt PJ, Grover GN, Roy-Byrne PP, et al. Thyroid function in women with premenstrual syndrome. J Clin Endocrinol Metab 1993; 76: 671–4

    Article  PubMed  CAS  Google Scholar 

  69. Girdler SS, Pedersen CA, Straneva PA, et al. Dysregulation of cardiovascular and neuroendocrine responses to stress in premenstrual dysphoric disorder. Psychiatry Res 1998; 81: 163–78

    Article  PubMed  CAS  Google Scholar 

  70. Woods NF, Lentz MJ, Mitchell ES, et al. Perceived stress, physiologic stress arousal, and premenstrual symptoms: group differences and intra-individual patterns. Res Nurs Health 1998; 21:511–23

    Article  PubMed  CAS  Google Scholar 

  71. Cahill CA. Differences in Cortisol, a stress hormone, in women with turmoil-type premenstrual symptoms. Nur Res 1998; 47: 278–84

    Article  CAS  Google Scholar 

  72. Steiner M, LePage P, Dunn EJ. Serotonin and gender specific psychiatric disorders. Int J Psychiatry Clin Pract 1997; 1:3–13

    Article  Google Scholar 

  73. Rapkin AJ. The role of serotonin in premenstrual syndrome. Clin Obstet Gynecol 1992; 35: 629–36

    Article  PubMed  CAS  Google Scholar 

  74. Rojansky N, Halbreich U, Zander K, et al. Imipramine receptor binding and serotonin uptake in platelets of women with premenstrual changes. Gynecol Obstet Invest 1991; 31: 146–52

    Article  PubMed  CAS  Google Scholar 

  75. Steiner M. Female-specific mood disorders. Clin Obstet Gynecol 1992; 35: 599–611

    Article  PubMed  CAS  Google Scholar 

  76. Yatham LN. Is 5-HT1A receptor subsensitivity a trait marker for late luteal phase dysphoric disorder? Apilot study. Can J Psychiatry 1993; 38: 662–4

    PubMed  CAS  Google Scholar 

  77. Wurtman JJ. Depression and weight gain: the serotonin connection. J Affect Disord 1993; 29: 183–92

    Article  PubMed  CAS  Google Scholar 

  78. Meltzer HY. Serotonergic dysfunction in depression. Br J Psychiatry 1989; 155 Suppl. 8: 25–31

    Google Scholar 

  79. Tuiten A, Panhuysen G, Koppeschaar H, et al. Stress, serotonergic function, and mood in users of oral contraceptives. Psychoneuroendocrinology 1995; 20: 323–34

    Article  PubMed  CAS  Google Scholar 

  80. Cohen IR, Wise PM. Effects of estradiol on the diurnal rhythm of serotonin activity in microdissected brain areas of ovariectomized rats. Endocrinology 1988; 122: 2619–25

    Article  PubMed  CAS  Google Scholar 

  81. Ladisich W. Influence of progesterone on serotonin metabolism: a possible causal factor for mood changes. Psychoneuroendocrinology 1977; 2: 257–66

    Article  PubMed  CAS  Google Scholar 

  82. Ashby Jr CR, Carr LA, Cook CL, et al. Alteration of platelet serotonergic mechanisms and monoamine oxidase activity in premenstrual syndrome. Biol Psychiatry 1988; 24: 225–33

    Article  PubMed  CAS  Google Scholar 

  83. Rapkin AJ, Edelmuth E, Chang LC, et al. Whole blood serotonin in premenstrual syndrome. Obstet Gynecol 1987; 70: 533–7

    PubMed  CAS  Google Scholar 

  84. Steege JF, Stout AL, Knight DL, et al. Reduced platelet tritium-labeled imipramine binding sites in women with premenstrual syndrome. Am J Obstet Gynecol 1992; 167: 168–72

    PubMed  CAS  Google Scholar 

  85. Taylor DL, Mathew RH, Ho BT, et al. Serotonin levels and platelet uptake during premenstrual tension. Neuropsychobiology 1984; 12: 16–8

    Article  PubMed  CAS  Google Scholar 

  86. Bancroft J, Cook A, Davidson D, et al. Blunting of neuroendocrine responses to infusion of L-tryptophan in women with perimenstrual mood change. Psychol Med 1991; 21: 305–12

    Article  PubMed  CAS  Google Scholar 

  87. Bancroft J, Cook A. The neuroendocrine response to d-fenfluramine in women with premenstrual depression. J Affect Disord 1995; 36: 57–64

    Article  PubMed  CAS  Google Scholar 

  88. Fitzgerald M, Malone K, Li S, et al. Blunted serotonin response to fenfluramine challenge in premenstrual dysphoric disorder. Am J Psychiatry 1997; 154: 556–8

    PubMed  CAS  Google Scholar 

  89. Steiner M, Yatham LN, Coote M, et al. Serotonergic dysfunction in women with pure premenstrual dysphoric disorder: is the fenfluramine challenge test still relevant? Psychiatry Res 1999; 87: 107–15

    Article  PubMed  CAS  Google Scholar 

  90. Su TP, Schmidt PJ, Danaceau M, et al. Effect of menstrual cycle phase on neuroendocrine and behavioral responses to the serotonin agonist m-chlorophenylpiperazine in women with premenstrual syndrome and controls. J Clin Endocrinol Metab 1997; 82: 1220–8

    Article  PubMed  CAS  Google Scholar 

  91. Menkes DB, Coates DC, Fawcett JP. Acute tryptophan depletion aggravates premenstrual syndrome. J Affect Disord 1994; 32: 37–44

    Article  PubMed  CAS  Google Scholar 

  92. Steiner M, Judge R, Kumar R. Serotonin re-uptake inhibitors in the treatment of premenstrual dysphoria: current state of knowledge. Int J Psychiatry Clin Pract 1997; 1: 241–7

    Article  CAS  Google Scholar 

  93. Halbreich U, Tworek H. Altered serotonergic activity in women with dysphoric premenstrual syndromes. Int J Psychiatry Med 1993; 23: 1–27

    Article  PubMed  CAS  Google Scholar 

  94. Leibenluft E, Fiero PL, Rubinow DR. Effects of the menstrual cycle on dependent variables in mood disorder research. Arch Gen Psychiatry 1994; 51: 761–81

    Article  PubMed  CAS  Google Scholar 

  95. Kouri EM, Halbreich U. State and trait abnormalities in women with dysphoric premenstrual syndromes. Psychopharmacol Bull 1997; 33: 767–70

    PubMed  CAS  Google Scholar 

  96. Sundstrom I, Andersson A, Nyberg S, et al. Patients with premenstrual syndrome have a different sensitivity to a neuroactive steroid during the menstrual cycle compared to control subjects. Neuroendocrinology 1998; 67: 126–38

    Article  PubMed  CAS  Google Scholar 

  97. Halbreich U, Petty F, Yonkers K, et al. Low plasma gamma-aminobutyric acid levels during the late luteal phase of women with premenstrual dysphoric disorder. Am J Psychiatry 1996; 153:718–20

    PubMed  CAS  Google Scholar 

  98. Gurguis GN, Yonkers KA, Phan SP, et al. Adrenergic receptors in premenstrual dysphoric disorder: I. Platelet α2 receptors: Gi protein coupling, phase of menstrual cycle, and prediction of luteal phase symptom severity. Biol Psychiatry 1998; 44: 600–9

    Article  PubMed  CAS  Google Scholar 

  99. Mortola JF. Premenstrual syndrome. Trends Endocrinol Metab 1996; 7: 184–9

    Article  PubMed  CAS  Google Scholar 

  100. Rapkin AJ, Shoupe D, Reading A, et al. Decreased central opioid activity in premenstrual syndrome: luteinizing hormone response to naloxone. J Soc Gynecol Invest 1996; 3: 93–8

    Article  CAS  Google Scholar 

  101. Chuong CJ, Coulam CB, Bergstralh EJ, et al. Clinical trial of naltrexone in premenstrual syndrome. Obstet Gynecol 1988; 72: 332

    PubMed  CAS  Google Scholar 

  102. Parry BL, Berga SL, Kripke DF, et al. Altered waveform of plasma nocturnal melatonin secretions in premenstrual depression. Arch Gen Psychiatry 1990; 47: 1139–46

    Article  PubMed  CAS  Google Scholar 

  103. Parry BL, Berga SL, Mostofi N, et al. Plasma melatonin circadian rhythms during the menstrual cycle and after light therapy in premenstrual dysphoric disorder and normal control subjects. J Biol Rhythms 1997; 12(1): 47–64

    Article  PubMed  CAS  Google Scholar 

  104. Parry BL, Udell C, Elliott JA, et al. Blunted phase-shift responses to morning bright light in premenstrual dysphoric disorder. J Biol Rhythms 1997; 12: 443–56

    PubMed  CAS  Google Scholar 

  105. Chuong CJ, Kim SR, Taskin O, et al. Sleep pattern changes in menstrual cycles of women with premenstrual syndrome: a preliminary study. Am J Obstet Gynecol 1997; 177: 554–48

    Article  PubMed  CAS  Google Scholar 

  106. Nakayama K, Nakagawa T, Hiyama T, et al. Circadian changes in body temperatures during the menstrual cycle of healthy adult females and patients suffering from premenstrual syndrome. Int J Clin Pharmacol Res 1997; 17: 155–64

    PubMed  CAS  Google Scholar 

  107. Parry BL, LeVeau B, Mostofi N, et al. Temperature circadian rhythms during the menstrual cycle and sleep deprivation in premenstrual dysphoric disorder and normal comparison subjects. J Biol Rhythms 1997; 12: 34–46

    Article  PubMed  CAS  Google Scholar 

  108. Kendler KS, Silberg JL, Neale MC, et al. Genetic and environmental factors in the aetiology of menstrual, premenstrual and neurotic symptoms: a population-based twin study. Psychol Med 1992; 22: 85–100

    Article  PubMed  CAS  Google Scholar 

  109. van den Akker OBA, Stein GS, Neale MC, et al. Genetic and environmental variation in menstrual cycle: histories of two British twin samples. Acta Genet Med Gemellol 1987; 36: 541–8

    PubMed  Google Scholar 

  110. Morse G. Positively refraining perceptions of the menstrual cycle among women with premenstrual syndrome. J Obstet Gynecol Neonatal Nurs 1999; 28: 165–74

    Article  PubMed  CAS  Google Scholar 

  111. Stotland NL, Harwood B. Social, political, and legal considerations. In: Gold JH, Severino SK, editors. Premenstrual dysphorias: myths and realities. Washington, DC: American Psychiatric Press, 1994: 185–200

    Google Scholar 

  112. Marvan ML, Escobedo C. Premenstrual symptomatology: role of prior knowledge about premenstrual syndrome. Psychosom Med 1999; 61: 163–7

    PubMed  CAS  Google Scholar 

  113. Fontaine KR, Seal A. Optimism, social support, and premenstrual dysphoria. J Clin Psychol 1997; 53: 243–7

    Article  PubMed  CAS  Google Scholar 

  114. Seideman RY. Effects of a premenstrual syndrome education program on premenstrual symptomatology. Health Care Women Int 1990; 11: 491–501

    Article  PubMed  CAS  Google Scholar 

  115. Walton J, Youngkin E. The effect of a support group on self-esteem of women with premenstrual syndrome. J Obstet Gynecol Neonatal Nurs 1987; 16: 174–8

    Article  PubMed  CAS  Google Scholar 

  116. Kraemer GR, Kraemer RR. Premenstrual syndrome: diagnosis and treatment experiences. J Women’s Health 1998; 7: 893–907

    Article  CAS  Google Scholar 

  117. Rubinow DR, Schmidt PJ, Roca CA. Hormone measures in reproductive endocrine-related mood disorders: diagnostic issues. Psychopharmacol Bull 1998; 34: 289–90

    PubMed  CAS  Google Scholar 

  118. Reid RL. Premenstrual syndrome. Curr Probl Obstet Gynecol Fert 1985; 8: 1–57

    Google Scholar 

  119. Mortola JF, Girton L, Beck L, et al. Diagnosis of premenstrual syndrome by a simple, prospective, and reliable instrument: the calendar of premenstrual experiences. Obstet Gynecol 1990; 76: 302–7

    PubMed  CAS  Google Scholar 

  120. Steiner M, Steinberg S, Stewart D, et al. Fluoxetine in the treatment of premenstrual dysphoria. N Engl J Med 1995; 332: 1529–34

    Article  PubMed  CAS  Google Scholar 

  121. Steiner M, Haskett RF, Carroll BJ. Premenstrual tension syndrome: the development of research diagnostic criteria and new rating scales. Acta Psychiatr Scand 1980; 62: 177–90

    Article  PubMed  CAS  Google Scholar 

  122. Steiner M, Streiner DL, Steinberg S, et al. The measurement of premenstrual mood symptoms. J Affect Disord 1999; 53:269–73

    Article  PubMed  CAS  Google Scholar 

  123. Hendrick V, Altshuler LL. Recurrent mood shifts of premenstrual dysphoric disorder can be mistaken for rapid-cycling bipolar II disorder. J Clin Psychiatry 1998; 59: 479–80

    Article  PubMed  CAS  Google Scholar 

  124. Macmillan I, Young A. Bipolar II disorder vs. premenstrual dysphoric disorder. J Clin Psychiatry 1999; 60: 409–10

    Article  PubMed  CAS  Google Scholar 

  125. Maskall DD, Lam RW, Misri S, et al. Seasonally of symptoms in women with late luteal phase dysphoric disorder. Am J Psychiatry 1997; 154: 1436–41

    PubMed  CAS  Google Scholar 

  126. Steiner M, Yonkers K. Depression in women, mood disorders associated with reproductive cyclicity. London: Martin Dunitz Ltd, 1998: 13–20

    Google Scholar 

  127. Brockington I. Menstrual psychosis. Arch Women’s Ment Health 1998; 1: 3–13

    Article  Google Scholar 

  128. Halbreich U. Premenstrual dysphoric disorders: a diversified cluster of vulnerability traits to depression. Acta Psychiatr Scand 1997; 95: 169–76

    Article  PubMed  CAS  Google Scholar 

  129. Odber J, Cawood EH, Bancroft J. Salivary Cortisol in women with and without perimenstrual mood changes. J Psychosom Res 1998; 45: 557–68

    Article  PubMed  CAS  Google Scholar 

  130. Facchinetti F, Tarabusi M, Nappi G. Premenstrual syndrome and anxiety disorders: a psychobiological link. Psychother Psychosom 1998; 67: 57–60

    Article  PubMed  CAS  Google Scholar 

  131. Ekholm UB, Ekholm NO, Bäckström T. Premenstrual syndrome: comparison between different methods to diagnose cyclicity using daily symptom ratings. Acta Obstet Gynecol Scand 1998; 77: 551–7

    Article  PubMed  CAS  Google Scholar 

  132. Gehlert S, Chang CH, Hartlage S. Establishing the diagnostic validity of premenstrual dysphoric disorder using Rasch analysis. J Outcome Meas 1997; 1:2–18

    PubMed  CAS  Google Scholar 

  133. Gehlert S, Chang CH, Hartlage S. Symptom patterns of premenstrual dysphoric disorder as defined in the DSM-IV. J Wornens Health 1999; 8: 75–85

    Article  CAS  Google Scholar 

  134. Rapkin AJ, Cedars M, Morgan M. Insulin-like growth factor-1 and insulin-like growth factor-binding protein-3 in women with premenstrual syndrome. Fertil Steril 1998; 70: 1077–80

    Article  PubMed  CAS  Google Scholar 

  135. Parry BL, Mostofi N, LeVeau B, et al. Sleep EEG studies during early and late partial sleep deprivation in premenstrual dysphoric disorder and normal control subjects. Psychiatry Res 1999; 85: 127–43

    Article  PubMed  CAS  Google Scholar 

  136. Wyatt KM, Dimmock PW, Jones PW, et al. Efficacy of vitamin B-6 in the treatment of premenstrual syndrome: systematic review. BMJ 1999; 318: 1375–81

    Article  PubMed  CAS  Google Scholar 

  137. Thys-Jacobs S, Starkey P, Bernstein D, et al. Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Am J Obstet Gynecol 1998; 179: 444–52

    Article  PubMed  CAS  Google Scholar 

  138. Walker AF, De Souza MC, Vickers MF, et al. Magnesium supplementation alleviates premenstrual symptoms of fluid retention. J Women’s Health 1998; 7: 1157–65

    Article  CAS  Google Scholar 

  139. Parry BL, Mahan AM, Mostofi N, et al. Light therapy of late luteal phasae dysphoric disorder: an extended study. Am J Psychiatry 1993; 150: 1417–9

    PubMed  CAS  Google Scholar 

  140. Parry BL. Light therapy of premenstrual depression. In: Lam RW, editor. Seasonal affective disorder and beyond. Washington, DC: American Psychiatric Press, 1998: 173–91

    Google Scholar 

  141. Lam RW, Carter D, Misri S, et al. A controlled study of light therapy in women with late luteal phase dysphoric disorder. Psychiatry Res 1999; 86: 185–92

    Article  PubMed  CAS  Google Scholar 

  142. Blake F, Salkovskis P, Gath D, et al. Cognitive therapy for premenstrual syndrome. J Pyschosom Res 1998; 45: 307–18

    Article  CAS  Google Scholar 

  143. Morse CA, Dennerstein L, Farrell E, et al. A comparison of hormone therapy, coping skills training, and relaxation for the relief of premenstrual syndrome. J Behav Med 1991; 14: 469–89

    Article  PubMed  CAS  Google Scholar 

  144. Pearlstein TB. Nonpharmacologic treatment of premenstrual syndrome. Psychiatr Ann 1996; 26: 590–4

    Google Scholar 

  145. Morse GG. Effect of positive refraining and social support on perception of perimenstrual changes among women with premenstrual syndrome. Health Care Women Int 1997; 18: 175–93

    Article  PubMed  CAS  Google Scholar 

  146. Su T-P, Schmidt PJ, Danaceau MA, et al. Fluoxetine in the treatment of premenstrual dysphoria. Neuropsychopharmacology 1997; 16: 346–56

    Article  PubMed  CAS  Google Scholar 

  147. Pearlstein TB, Stone AB, Lund SA, et al. Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder. J Clin Psychopharmacol 1997; 17: 261–6

    Article  PubMed  CAS  Google Scholar 

  148. Steiner M, Korzekwa M, Lamont J, et al. Intermittent fluoxetine dosing in the treatment of women with premenstrual dysphoria. Psychopharmacol Bull 1997; 33: 771–4

    PubMed  CAS  Google Scholar 

  149. Diegoli MS, da Fonseca AM, Diegoli CA, et al. A double-blind trial of four medications to treat severe premenstrual syndrome. Int J Gynaecol Obstet 1998; 62: 63–7

    Article  PubMed  CAS  Google Scholar 

  150. Yonkers KA, Halbreich U, Freeman E, et al. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. JAMA 1997; 278: 983–8

    Article  PubMed  CAS  Google Scholar 

  151. Young SA, Hurt PH, Benedek DM, et al. Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: a randomized, double-blind, placebo-controlled crossover trial. J Clin Psychiatry 1998; 59: 76–80

    Article  PubMed  CAS  Google Scholar 

  152. Jermaine DM, Preece CK, Sykes RL, et al. Luteal phase sertraline treatment for premenstrual dysphoric disorder. Results of a double-blind, placebo-controlled, crossover study. Arch Fam Med 1999; 8: 328–32

    Article  Google Scholar 

  153. Halbreich U, Smoller JW. Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome. J Clin Psychiatry 1997; 58: 399–402

    Article  PubMed  CAS  Google Scholar 

  154. Freeman EW, Rickels K, Arredondo F, et al. Full- or half-cycle treatment of severe premenstrual syndrome with a serotonergic antidepressant. J Clin Psychopharmacol 1999; 19: 3–8

    Article  PubMed  CAS  Google Scholar 

  155. Eriksson E, Hedberg MA, Andersch B, et al. The serotonin reuptake inhibitor paroxetine is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacol 1995; 12: 167–76

    Article  CAS  Google Scholar 

  156. Sundblad C, Wikander I, Andersch B, et al. A naturalistic study of paroxetine in premenstrual syndrome: efficacy and side-effects during ten cycles of treatment. Eur Neuropsychopharmacol 1997; 7: 201–6

    Article  PubMed  CAS  Google Scholar 

  157. Wikander I, Sundblad C, Andersch B, et al. Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle? J Clin Psychopharmacol 1998; 18: 390–8

    Article  PubMed  CAS  Google Scholar 

  158. Sundblad C, Modigh K, Andersch B, et al. Clomipramine effectively reduces premenstrual irritability and dysphoria: a placebo controlled trial. Acta Psychiatr Scand 1992; 85: 39–47

    Article  PubMed  CAS  Google Scholar 

  159. Sundblad C, Hedberg MA, Eriksson E. Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo controlled trial. Neuropsychopharmacol 1993; 9: 133–45

    CAS  Google Scholar 

  160. Steinberg S, Annable L, Young SN, et al. A placebo-controlled clinical trial of L-tryptophan in premenstrual dysphoria. Biol Psychiatry 1999; 45: 313–20

    Article  PubMed  CAS  Google Scholar 

  161. Harrison WM, Endicott J, Rabkin JG, et al. Treatment of premenstrual dysphoria with alprazolam and placebo. Psychopharmacol Bull 1987; 23: 150–3

    PubMed  CAS  Google Scholar 

  162. Smith S, Rinehart JS, Ruddock VE, et al. Treatment of premenstrual syndrome with alprazolam: results of a double-blind, placebo-controlled, randomized crossover trial. Obstet Gynecol 1987; 70: 37–43

    PubMed  CAS  Google Scholar 

  163. Harrison WM, Endicott J, Nee J. Treatment of premenstrual dysphoria with alprazolam. Arch Gen Psychiatry 1990; 47: 270–5

    Article  PubMed  CAS  Google Scholar 

  164. Berger CP, Presser B. Alprazolam in the treatment of two subsamples of patients with late luteal phase dysphoric disorder: a double-blind, placebo-controlled crossover study. Obstet Gynecol 1994; 84: 379–85

    PubMed  CAS  Google Scholar 

  165. Freeman EW, Rickels K, Sondheimer SJ, et al. A double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome. JAMA 1995; 274: 51–7

    Article  PubMed  CAS  Google Scholar 

  166. Rickels K, Freeman E, Sondheimer S. Buspirone in treatment of premenstrual syndrome [letter]. Lancet 1989; I: 777

    Article  Google Scholar 

  167. Brown CS, Ling FW, Farmer RG, et al. Buspirone in the treatment of premenstrual syndrome. Drug Ther 1990; 20 Suppl. : 112–21

    Google Scholar 

  168. Sarno AP, Miller Jr EJ, Lundblad EG. Premenstrual syndrome: beneficial effects of periodic low-dose danazol. Obstet Gynecol 1987; 70: 33–6

    PubMed  Google Scholar 

  169. Hahn PM, VanVugt DA, Reid RL. A randomized, placebo-controlled crossover trial of danazol for the treatment of premenstrual syndrome. Psychoneuroendocrinology 1995; 20:193–209

    Article  PubMed  CAS  Google Scholar 

  170. O’Brien PM, Abukhalil IE. Randomized controlled trial of the management of premenstrual syndrome and premenstrual mastalgia using luteal phase-only danazol. Am J Obstet Gynecol 1999; 180 (1 Pt 1): 18–23

    Article  PubMed  Google Scholar 

  171. Brown CS, Ling FW, Andersen RN, et al. Efficacy of depot leuprolide in premenstrual syndrome: effect of symptom severity and type in a controlled trial. Obstet Gynecol 1994; 84: 779–86

    PubMed  CAS  Google Scholar 

  172. Freeman EW, Sondheimer SJ, Rickels K. Gonadotropin-releasing hormone agonist in the treatment of premenstrual symptoms with and without ongoing dysphoria: a controlled study. Psychopharmacol Bull 1997; 33: 303–9

    PubMed  CAS  Google Scholar 

  173. Mezrow G, Shoupe D, Spicer D, et al. Depot leuprolide acetate with estrogen and progestin add-back for long-term treatment of premenstrual syndrome. Fertil Steril 1994; 62: 932–7

    PubMed  CAS  Google Scholar 

  174. Hammarback S, Bäckström T. Induced anovulation as treatment of premenstrual tension syndrome. A double-blind cross-over study with GnRH-agonist versus placebo. Acta Obstet Gynaecol Scand 1988; 67: 159–66

    Article  CAS  Google Scholar 

  175. Bancroft J, Boyle H, Warner P, et al. The use of an LHRH agonist, buserelin, in the long-term management of premenstrual syndromes. Clin Endocrinol 1987; 27: 171–82

    Article  CAS  Google Scholar 

  176. West CP, Hillier H. Ovarian suppression with the gonadotrophin-releasing hormone agonist goserelin (Zoladex) in management of the premenstrual tension syndrome. Hum Reprod 1994; 9: 1058–63

    PubMed  CAS  Google Scholar 

  177. Smith RN, Studd JW, Zamblera D, et al. A randomised comparison over 8 months of 100 micrograms and 200 micrograms twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome. Br J Obstet Gynaecol 1995; 102: 475–84

    Article  PubMed  CAS  Google Scholar 

  178. Eriksson E. Serotonin reuptake inhibitors for the treatment of premenstrual dysphoria. Int Clin Psychopharmacol 1999; 14 Suppl. 2: S27–S33

    PubMed  Google Scholar 

  179. Freeman EW, Rickels K, Sondheimer SJ, et al. Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: a randomized controlled trial. Arch Gen Psychiatry 1999; 56: 932–9

    Article  PubMed  CAS  Google Scholar 

  180. Schmidt PJ, Grover GN, Rubinow DR. Alprazolam in the treatment of premenstrual syndrome. A double-blind, placebo-controlled trial. Arch Gen Psychiatry 1993; 50: 467–73

    Article  PubMed  CAS  Google Scholar 

  181. Evans SM, Haney M, Levin FR, et al. Mood and performance changes in women with premenstrual dysphoric disorder: acute effects of alprazolam. Neuropsychopharmacology 1998; 19: 499–516

    Article  PubMed  CAS  Google Scholar 

  182. Evans SM, Foltin RW, Fischman MW. Food ‘cravings’ and the acute effects of alprazolam on food intake in women with premenstrual dysphoric disorder. Appetite 1999; 32: 331–49

    Article  PubMed  CAS  Google Scholar 

  183. Sundstrom I, Nyberg S, Bixo M, et al. Treatment of premenstrual syndrome with gonadotropin-releasing hormone agonist in a low dose regimen. Acta Obstet Gynecol Scand 1999; 78: 891–9

    Article  PubMed  CAS  Google Scholar 

  184. Leather AT, Studd JW, Watson NR, et al. The treatment of severe premenstrual syndrome with goserelin with and without ‘add-back’ estrogen therapy: a placebo-controlled study. Gynecol Endocrinol 1999; 13: 48–55

    Article  PubMed  CAS  Google Scholar 

  185. Watson NR, Studd JW, Savvas M, et al. Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet 1989; II: 730–2

    Article  Google Scholar 

  186. Bäckström T, Hansson-Malmstrom Y, Lindhe BA, et al. Oral contraceptives in premenstrual syndrome: a randomized comparison of triphasic and monophasic preparations. Contraception 1992; 46: 253–68

    Article  PubMed  Google Scholar 

  187. Graham CA, Sherwin BB. A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive. J Psychosom Res 1992; 36: 257–66

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Ontario, Canada

    Meir Steiner (Director)

  2. Women’s Health Concerns Clinic, Room FB639, St Joseph’s Hospital, 50 Charlton Avenue East, Hamilton, Ontario, L8N 4A6, Canada

    Meir Steiner (Director) & Leslie Born

  3. Father Sean O’Sullivan Research Centre, St Joseph’s Hospital, Hamilton, Ontario, Canada

    Meir Steiner (Director) & Leslie Born

Authors
  1. Meir Steiner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Leslie Born
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Meir Steiner.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Steiner, M., Born, L. Advances in the Diagnosis and Treatment of Premenstrual Dysphoria. Mol Diag Ther 13, 287–304 (2000). https://doi.org/10.2165/00023210-200013040-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-200013040-00005

Keywords

Search

Navigation